Background: Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient outcomes during vedolizumab treatment in UC. Methods: Prospectively scored maintenance clinical (26.5 weeks; interquartile range [IQR], 16.3-37.0 weeks) and endoscopic (23.5 weeks; IQR, 16.8-35.6 weeks) outcomes were compared with serum vedolizumab concentrations, antivedolizumab antibodies, and serum biomarkers at baseline and weeks 2, 6, 14, and 26. A linear mixed-effects model compared biomarker trajectories over time between clinical and endoscopic remitters and nonremitters. Results: Thirty-two patients were included. Soluble (s)-tumor necrosis factor (TNF)-α, s-α4β7, s-mucosal addressin cell adhesion molecule (s-MAdCAM-1), and s-amyloid A (s-AA) significantly changed with treatment. A linear mixed-effects model demonstrated that s-α4β7 (P = 0.044) increased and s-MAdCAM-1 (P = 0.006) and s-vascular cell adhesion molecule-1 (s-VCAM-1, P = 0.001) decreased more rapidly in patients achieving clinical remission in maintenance. S-MAdCAM-1 (P = 0.005), s-intracellular adhesion molecule-1 (ICAM-1; P = 0.014), s-VCAM-1 (P < 0.001), and s-TNF (P = 0.052) decreased more rapidly in endoscopic remitters. In clinical remitters, higher week 14 (20.3 ng/mL vs 6.0 ng/mL; P = 0.013) and week 26 (14.1 ng/mL vs 8.6 ng/mL; P = 0.05) s-α4β7 were observed. In endoscopic remitters, week 2 (6.7 pg/mL vs 17.8 pg/mL; P = 0.038) and week 6 (3.9 pg/mL vs 15.6 pg/mL; P = 0.005) s-TNF and week 14 s-VCAM (589.1 ng/mL vs 746.0 ng/mL; P = 0.05) were lower. Conclusion: Serum biomarkers were associated with outcomes in vedolizumab-treated UC patients. s-α4β7 increased, whereas s-MAdCAM-1, s-VCAM-1, s-ICAM-1, and s-TNF decreased more rapidly in remitters. At individual time points, induction s-TNF and maintenance s-VCAM-1 concentrations were lower, whereas maintenance s-α4β7 concentrations were higher in remitters.
Background: Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient outcomes during vedolizumab treatment in UC. Methods: Prospectively scored maintenance clinical (26.5 weeks; interquartile range [IQR], 16.3-37.0 weeks) and endoscopic (23.5 weeks; IQR, 16.8-35.6 weeks) outcomes were compared with serum vedolizumab concentrations, antivedolizumab antibodies, and serum biomarkers at baseline and weeks 2, 6, 14, and 26. A linear mixed-effects model compared biomarker trajectories over time between clinical and endoscopic remitters and nonremitters. Results: Thirty-two patients were included. Soluble (s)-tumor necrosis factor (TNF)-α, s-α4β7, s-mucosal addressin cell adhesion molecule (s-MAdCAM-1), and s-amyloid A (s-AA) significantly changed with treatment. A linear mixed-effects model demonstrated that s-α4β7 (P = 0.044) increased and s-MAdCAM-1 (P = 0.006) and s-vascular cell adhesion molecule-1 (s-VCAM-1, P = 0.001) decreased more rapidly in patients achieving clinical remission in maintenance. S-MAdCAM-1 (P = 0.005), s-intracellular adhesion molecule-1 (ICAM-1; P = 0.014), s-VCAM-1 (P < 0.001), and s-TNF (P = 0.052) decreased more rapidly in endoscopic remitters. In clinical remitters, higher week 14 (20.3 ng/mL vs 6.0 ng/mL; P = 0.013) and week 26 (14.1 ng/mL vs 8.6 ng/mL; P = 0.05) s-α4β7 were observed. In endoscopic remitters, week 2 (6.7 pg/mL vs 17.8 pg/mL; P = 0.038) and week 6 (3.9 pg/mL vs 15.6 pg/mL; P = 0.005) s-TNF and week 14 s-VCAM (589.1 ng/mL vs 746.0 ng/mL; P = 0.05) were lower. Conclusion: Serum biomarkers were associated with outcomes in vedolizumab-treated UC patients. s-α4β7 increased, whereas s-MAdCAM-1, s-VCAM-1, s-ICAM-1, and s-TNF decreased more rapidly in remitters. At individual time points, induction s-TNF and maintenance s-VCAM-1 concentrations were lower, whereas maintenance s-α4β7 concentrations were higher in remitters.
Authors: Séverine Vermeire; William J Sandborn; Silvio Danese; Xavier Hébuterne; Bruce A Salzberg; Maria Klopocka; Dino Tarabar; Tomas Vanasek; Miloš Greguš; Paul A Hellstern; Joo Sung Kim; Miles P Sparrow; Kenneth J Gorelick; Michelle Hinz; Alaa Ahmad; Vivek Pradhan; Mina Hassan-Zahraee; Robert Clare; Fabio Cataldi; Walter Reinisch Journal: Lancet Date: 2017-05-17 Impact factor: 79.321
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: W Yacoub; N Williet; L Pouillon; T Di-Bernado; M De Carvalho Bittencourt; S Nancey; A Lopez; S Paul; C Zallot; X Roblin; L Peyrin-Biroulet Journal: Aliment Pharmacol Ther Date: 2018-01-31 Impact factor: 8.171
Authors: Andres J Yarur; Maria A Quintero; Anjali Jain; Frank Czul; Jamie S Barkin; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2017-01 Impact factor: 5.325
Authors: Maria Gonzalez-Vivo; Minna K Lund Tiirikainen; Montserrat Andreu; Agnes Fernandez-Clotet; Alicia López-García; Francisca Murciano Gonzalo; Lourdes Abril Rodriguez; Carmen de Jesús-Gil; Ester Ruiz-Romeu; Lídia Sans-de San Nicolàs; Lluis F Santamaria-Babí; Lucía Márquez-Mosquera Journal: Front Med (Lausanne) Date: 2022-06-15
Authors: Lorenzo Bertani; Gian Paolo Caviglia; Luca Antonioli; Rinaldo Pellicano; Sharmila Fagoonee; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Corrado Blandizzi; Francesco Costa; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-05-02 Impact factor: 4.241
Authors: Ariela K Holmer; Robert Battat; Parambir S Dulai; Niels Vande Casteele; Nghia Nguyen; Anjali Jain; Ara Miralles; Jennifer Neill; Helen Le; Siddharth Singh; Jesus Rivera-Nieves; William J Sandborn; Brigid S Boland Journal: Therap Adv Gastroenterol Date: 2020-11-12 Impact factor: 4.409